

Graeme Milligan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5720133/publications.pdf>

Version: 2024-02-01

472
papers

27,004
citations

4960

84
h-index

10732

138
g-index

485
all docs

485
docs citations

485
times ranked

18536
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of a serotonin/glutamate receptor complex implicated in psychosis. <i>Nature</i> , 2008, 452, 93-97.	27.8	739
2	Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers. <i>Journal of Neuroscience</i> , 2006, 26, 2080-2087.	3.6	553
3	G Protein-Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. <i>Pharmacological Reviews</i> , 2014, 66, 413-434.	16.0	497
4	Tailoring cAMP-signalling responses through isoform multiplicity. <i>Trends in Biochemical Sciences</i> , 1997, 22, 217-224.	7.5	417
5	G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology. <i>Molecular Pharmacology</i> , 2004, 66, 1-7.	2.3	366
6	Building a new conceptual framework for receptor heteromers. <i>Nature Chemical Biology</i> , 2009, 5, 131-134.	8.0	349
7	Heterotrimeric G-proteins: a short history. <i>British Journal of Pharmacology</i> , 2006, 147, S46-S55.	5.4	347
8	G-Protein-Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor. <i>Circulation</i> , 2005, 111, 1806-1813.	1.6	346
9	The dynamic role of palmitoylation in signal transduction. <i>Trends in Biochemical Sciences</i> , 1995, 20, 181-186.	7.5	312
10	G protein-coupled receptor heterodimerization: contribution to pharmacology and function. <i>British Journal of Pharmacology</i> , 2009, 158, 5-14.	5.4	303
11	International Union of Pharmacology. LXXI. Free Fatty Acid Receptors FFA1, -2, and -3: Pharmacology and Pathophysiological Functions. <i>Pharmacological Reviews</i> , 2008, 60, 405-417.	16.0	293
12	The experimental power of FR900359 to study Gq-regulated biological processes. <i>Nature Communications</i> , 2015, 6, 10156.	12.8	282
13	International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers. <i>Pharmacological Reviews</i> , 2007, 59, 5-13.	16.0	274
14	Inverse agonism: pharmacological curiosity or potential therapeutic strategy?. <i>Trends in Pharmacological Sciences</i> , 1995, 16, 10-13.	8.7	270
15	Abolition of the expression of inhibitory guanine nucleotide regulatory protein Gi activity in diabetes. <i>Nature</i> , 1987, 327, 229-232.	27.8	248
16	Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. <i>Nature Biotechnology</i> , 2010, 28, 943-949.	17.5	246
17	Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes. <i>Pharmacological Reviews</i> , 2010, 62, 701-725.	16.0	246
18	Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective: TABLE 1. <i>Molecular Pharmacology</i> , 2003, 64, 1271-1276.	2.3	239

#	ARTICLE	IF	CITATIONS
19	Receptor for the Pain Modulatory Neuropeptides FF and AF Is an Orphan G Protein-coupled Receptor. <i>Journal of Biological Chemistry</i> , 2000, 275, 25965-25971.	3.4	233
20	Monitoring Receptor Oligomerization Using Time-resolved Fluorescence Resonance Energy Transfer and Bioluminescence Resonance Energy Transfer. <i>Journal of Biological Chemistry</i> , 2001, 276, 14092-14099.	3.4	227
21	Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production. <i>Cell Reports</i> , 2020, 30, 2934-2947.e6.	6.4	221
22	Complex Pharmacology of Free Fatty Acid Receptors. <i>Chemical Reviews</i> , 2017, 117, 67-110.	47.7	209
23	The Pharmacology and Function of Receptors for Short-Chain Fatty Acids. <i>Molecular Pharmacology</i> , 2016, 89, 388-398.	2.3	206
24	Methods to monitor the quaternary structure of G protein-coupled receptors. <i>FEBS Journal</i> , 2005, 272, 2914-2925.	4.7	203
25	A Bioluminescent Assay for Agonist Activity at Potentially Any G-Protein-Coupled Receptor. <i>Analytical Biochemistry</i> , 1997, 252, 115-126.	2.4	201
26	Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. <i>Biochemical Journal</i> , 2002, 365, 429-440.	3.7	197
27	Orexin-1 Receptor-Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand-dependent and -independent Coordinated Alterations of Receptor Localization and Function. <i>Journal of Biological Chemistry</i> , 2006, 281, 38812-38824.	3.4	197
28	Metabolism meets immunity: The role of free fatty acid receptors in the immune system. <i>Biochemical Pharmacology</i> , 2016, 114, 3-13.	4.4	197
29	β -Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. <i>Nature</i> , 2016, 531, 661-664.	27.8	190
30	Principles: Extending the utility of [³⁵ S]GTP γ S binding assays. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 87-90.	8.7	184
31	β -Arrestin 1 and G α q/11 Coordinately Activate RhoA and Stress Fiber Formation following Receptor Stimulation. <i>Journal of Biological Chemistry</i> , 2005, 280, 8041-8050.	3.4	180
32	Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production. <i>ISME Journal</i> , 2018, 12, 610-622.	9.8	173
33	The Pharmacology of TUC-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism. <i>Molecular Pharmacology</i> , 2013, 84, 710-725.	2.3	172
34	Antibodies to the GTP binding protein, Go, antagonize noradrenaline-induced calcium current inhibition in NG108-15 hybrid cells. <i>Neuron</i> , 1989, 3, 177-182.	8.1	165
35	Allosteric modulation of heterodimeric G-protein-coupled receptors. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 615-620.	8.7	162
36	Purification of heterotrimeric GTP-binding proteins from brain: identification of a novel form of Go. <i>Biochemistry</i> , 1988, 27, 7085-7090.	2.5	160

#	ARTICLE	IF	CITATIONS
37	Use of specific antibodies to quantitate the guanine nucleotide-binding protein Go in brain.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 2258-2262.	7.1	157
38	The β 1b-Adrenoceptor Exists as a Higher-Order Oligomer: Effective Oligomerization Is Required for Receptor Maturation, Surface Delivery, and Function. Molecular Pharmacology, 2007, 71, 1015-1029.	2.3	154
39	Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nature Protocols, 2011, 6, 1748-1760.	12.0	154
40	Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. Cell Metabolism, 2009, 10, 139-147.	16.2	151
41	Mechanisms of multifunctional signalling by G protein-linked receptors. Trends in Pharmacological Sciences, 1993, 14, 239-244.	8.7	150
42	G protein-coupled receptor dimerisation: Molecular basis and relevance to function. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 825-835.	2.6	149
43	Derivation of Endothelial Cells From Human Embryonic Stem Cells by Directed Differentiation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1389-1397.	2.4	147
44	Discovery of a Potent and Selective GPR120 Agonist. Journal of Medicinal Chemistry, 2012, 55, 4511-4515.	6.4	145
45	Targeted Elimination of G Proteins and Arrestins Defines Their Specific Contributions to Both Intensity and Duration of G Protein-coupled Receptor Signaling. Journal of Biological Chemistry, 2016, 291, 27147-27159.	3.4	143
46	Immunological Analysis of Glucose Transporters Expressed in Different Regions of the Rat Brain and Central Nervous System. Biochemical and Biophysical Research Communications, 1993, 192, 1297-1302.	2.1	138
47	Inverse agonism and the regulation of receptor number. Trends in Pharmacological Sciences, 1997, 18, 468-474.	8.7	134
48	Bradykinin excites rat sympathetic neurons by inhibition of M current through a mechanism involving B2 receptors and $G_{\beta 11}$. Neuron, 1995, 14, 399-405.	8.1	132
49	The chemokine receptor CXCR2 mediates effective scavenging of CCL19 <i>in vitro</i> . European Journal of Immunology, 2006, 36, 1904-1916.	2.9	127
50	The insulin receptor tyrosyl kinase phosphorylates holomeric forms of the guanine nucleotide regulatory proteins Gi and Go. FEBS Letters, 1987, 212, 281-288.	2.8	126
51	BRET analysis of GPCR oligomerization: newer does not mean better. Nature Methods, 2007, 4, 3-4.	19.0	126
52	Techniques: Promiscuous G_{β} proteins in basic research and drug discovery. Trends in Pharmacological Sciences, 2005, 26, 595-602.	8.7	125
53	G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discovery Today, 2006, 11, 541-549.	6.4	124
54	Agonist regulation of cellular G protein levels and distribution: mechanisms and functional implications. Trends in Pharmacological Sciences, 1993, 14, 413-418.	8.7	122

#	ARTICLE	IF	CITATIONS
55	Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT _{2A} -mGlu ₂) Receptor Heteromerization and Its Psychoactive Behavioral Function. <i>Journal of Biological Chemistry</i> , 2012, 287, 44301-44319.	3.4	122
56	Applications of bioluminescence- and fluorescence resonance energy transfer to drug discovery at G protein-coupled receptors. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 397-405.	4.0	119
57	Extracellular Ionic Locks Determine Variation in Constitutive Activity and Ligand Potency between Species Orthologs of the Free Fatty Acid Receptors FFA2 and FFA3. <i>Journal of Biological Chemistry</i> , 2012, 287, 41195-41209.	3.4	116
58	Î ² -Arrestin 2-Dependent Angiotensin II Type 1A Receptor-Mediated Pathway of Chemotaxis. <i>Molecular Pharmacology</i> , 2005, 67, 1229-1236.	2.3	115
59	G16 as a universal G protein adapter: implications for agonist screening strategies. <i>Trends in Pharmacological Sciences</i> , 1996, 17, 235-237.	8.7	114
60	The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. <i>Current Opinion in Pharmacology</i> , 2010, 10, 23-29.	3.5	114
61	Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. <i>Clinical Science</i> , 2014, 126, 815-827.	4.3	114
62	Protein-protein interactions at G-protein-coupled receptors. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 513-518.	8.7	113
63	The CXCR1 and CXCR2 Receptors Form Constitutive Homo- and Heterodimers Selectively and with Equal Apparent Affinities. <i>Journal of Biological Chemistry</i> , 2005, 280, 28663-28674.	3.4	113
64	Insights into ligand pharmacology using receptor-G-protein fusion proteins. <i>Trends in Pharmacological Sciences</i> , 2000, 21, 24-28.	8.7	109
65	Agonist-Induced Endocytosis and Recycling of the Gonadotropin-Releasing Hormone Receptor: Effect of Î ² -Arrestin on Internalization Kinetics. <i>Molecular Endocrinology</i> , 1998, 12, 1818-1829.	3.7	105
66	Dimers of Class A G Protein-coupled Receptors Function via Agonist-mediated Trans-activation of Associated G Proteins. <i>Journal of Biological Chemistry</i> , 2003, 278, 42578-42587.	3.4	101
67	Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species. <i>Science Signaling</i> , 2010, 3, ra20.	3.6	101
68	Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists. <i>Journal of Biological Chemistry</i> , 2011, 286, 10628-10640.	3.4	101
69	Defining the Molecular Basis for the First Potent and Selective Orthosteric Agonists of the FFA2 Free Fatty Acid Receptor. <i>Journal of Biological Chemistry</i> , 2013, 288, 17296-17312.	3.4	99
70	Antibodies against the carboxyl-terminal 5-kDa peptide of the alpha subunit of transducin crossreact with the 40-kDa but not the 39-kDa guanine nucleotide binding protein from brain.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985, 82, 4095-4099.	7.1	98
71	Mechanism and Function of <i>Drosophila</i> <i>capa</i> GPCR: A Desiccation Stress-Responsive Receptor with Functional Homology to Human NeuromedinU Receptor. <i>PLoS ONE</i> , 2012, 7, e29897.	2.5	98
72	Conserved Polar Residues in Transmembrane Domains V, VI, and VII of Free Fatty Acid Receptor 2 and Free Fatty Acid Receptor 3 Are Required for the Binding and Function of Short Chain Fatty Acids. <i>Journal of Biological Chemistry</i> , 2008, 283, 32913-32924.	3.4	96

#	ARTICLE	IF	CITATIONS
73	Multiple Interactions between Transmembrane Helices Generate the Oligomeric β 1b-Adrenoceptor. <i>Molecular Pharmacology</i> , 2004, 66, 1123-1137.	2.3	95
74	The Prevalence, Maintenance, and Relevance of G Protein-coupled Receptor Oligomerization. <i>Molecular Pharmacology</i> , 2013, 84, 158-169.	2.3	95
75	GPCR homo-oligomerization. <i>Current Opinion in Cell Biology</i> , 2019, 57, 40-47.	5.4	94
76	The Dually Acylated NH2-terminal Domain of Gi1 β Is Sufficient to Target a Green Fluorescent Protein Reporter to Caveolin-enriched Plasma Membrane Domains. <i>Journal of Biological Chemistry</i> , 1999, 274, 5843-5850.	3.4	93
77	Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. <i>British Journal of Nutrition</i> , 2015, 113, 1677-1688.	2.3	93
78	Role of MicroRNAs 99b, 181a, and 181b in the Differentiation of Human Embryonic Stem Cells to Vascular Endothelial Cells. <i>Stem Cells</i> , 2012, 30, 643-654.	3.2	92
79	Treatment of intact hepatocytes with either the phorbol ester TPA or glucagon elicits the phosphorylation and functional inactivation of the inhibitory guanine nucleotide regulatory protein Gi. <i>FEBS Letters</i> , 1989, 243, 77-82.	2.8	91
80	Localization of the succinate receptor in the distal nephron and its signaling in polarized MDCK cells. <i>Kidney International</i> , 2009, 76, 1258-1267.	5.2	91
81	Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β 2-arrestin-2 and activate Gi13. <i>Biochemical Journal</i> , 2010, 432, 451-459.	3.7	91
82	Real-time monitoring of redox changes in the mammalian endoplasmic reticulum. <i>Journal of Cell Science</i> , 2011, 124, 2349-2356.	2.0	91
83	Allosteric signaling through an mGlu2 and 5-HT _{2A} heteromeric receptor complex and its potential contribution to schizophrenia. <i>Science Signaling</i> , 2016, 9, ra5.	3.6	91
84	Chimaeric Gi β proteins: their potential use in drug discovery. <i>Trends in Pharmacological Sciences</i> , 1999, 20, 118-124.	8.7	88
85	Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of β 2-arrestin using spot-immobilized peptide arrays. <i>Biochemical Journal</i> , 2007, 404, 71-80.	3.7	88
86	<i>Staphylococcus aureus</i> Staphopain A inhibits CXCR2-dependent neutrophil activation and chemotaxis. <i>EMBO Journal</i> , 2012, 31, 3607-3619.	7.8	88
87	The GTP-binding regulatory proteins of neuroblastoma Å— glioma, NG108-15, and glioma, C6, cells. <i>FEBS Letters</i> , 1986, 195, 225-230.	2.8	87
88	Hydrophobicity of Residue351 of the G Protein Gi1 β Determines the Extent of Activation by the β 2A-Adrenoceptor. <i>Biochemistry</i> , 1998, 37, 11555-11562.	2.5	87
89	Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12195-12200.	7.1	87
90	Combinatorial expression of GPCR isoforms affects signalling and drug responses. <i>Nature</i> , 2020, 587, 650-656.	27.8	87

#	ARTICLE	IF	CITATIONS
91	Angiotensin I ϵ 9 antagonises pro ϵ hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. <i>Journal of Physiology</i> , 2011, 589, 939-951.	2.9	84
92	Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse μ opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation. <i>Biochemical Journal</i> , 1996, 320, 227-235.	3.7	83
93	Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A. <i>Journal of Biological Chemistry</i> , 2011, 286, 37414-37428.	3.4	81
94	Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8868-8878.	6.4	81
95	GPCR dimerisation. <i>Life Sciences</i> , 2003, 74, 181-188.	4.3	80
96	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. <i>Frontiers in Endocrinology</i> , 2014, 5, 137.	3.5	80
97	The β Subunit of Gq Contributes to Muscarinic Inhibition of the M-Type Potassium Current in Sympathetic Neurons. <i>Journal of Neuroscience</i> , 1998, 18, 4521-4531.	3.6	79
98	Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors. <i>Journal of Biological Chemistry</i> , 2008, 283, 11424-11434.	3.4	78
99	Extracellular Loop 2 of the Free Fatty Acid Receptor 2 Mediates Allosterism of a Phenylacetamide Ago-Allosteric Modulator. <i>Molecular Pharmacology</i> , 2011, 80, 163-173.	2.3	78
100	Domain Swapping in the Human Histamine H ₁ Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 131-138.	2.5	77
101	Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS. <i>Journal of Biological Chemistry</i> , 2006, 281, 16757-16767.	3.4	77
102	Uncovering the Pharmacology of the G Protein-Coupled Receptor GPR40: High Apparent Constitutive Activity in Guanosine 5 ϵ -O-(3-[³⁵ S]thio)triphosphate Binding Studies Reflects Binding of an Endogenous Agonist. <i>Molecular Pharmacology</i> , 2007, 71, 994-1005.	2.3	77
103	FFA4/GPR120: Pharmacology and Therapeutic Opportunities. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 809-821.	8.7	77
104	Interactions of the β 2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants. <i>Biochemical Journal</i> , 1997, 321, 721-728.	3.7	76
105	CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2 ϵ DOP receptor heterodimer. <i>Biochemical Journal</i> , 2008, 412, 245-256.	3.7	76
106	Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN- γ production in mice. <i>Journal of Clinical Investigation</i> , 2007, 117, 3507-3518.	8.2	76
107	The G Protein β Subunit Has a Key Role in Determining the Specificity of Coupling to, but Not the Activation of, G Protein-gated Inwardly Rectifying K ⁺ Channels. <i>Journal of Biological Chemistry</i> , 2000, 275, 921-929.	3.4	75
108	Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. <i>FASEB Journal</i> , 2012, 26, 4951-4965.	0.5	75

#	ARTICLE	IF	CITATIONS
109	Interactions between the Mas-Related Receptors MrgD and MrgE Alter Signalling and Trafficking of MrgD. <i>Molecular Pharmacology</i> , 2006, 69, 479-491.	2.3	74
110	The Action and Mode of Binding of Thiazolidinedione Ligands at Free Fatty Acid Receptor 1. <i>Journal of Biological Chemistry</i> , 2009, 284, 17527-17539.	3.4	74
111	GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. <i>Bioinformatics</i> , 2010, 26, 1804-1805.	4.1	74
112	Insulin activates glycerol-3-phosphate acyltransferase (de novo phosphatidic acid synthesis) through a phospholipid-derived mediator. Apparent involvement of Gi.alpha. and activation of a phospholipase C. <i>Biochemistry</i> , 1990, 29, 8735-8740.	2.5	73
113	Modulation of SF1 Neuron Activity Coordinately Regulates Both Feeding Behavior and Associated Emotional States. <i>Cell Reports</i> , 2017, 21, 3559-3572.	6.4	73
114	Ligand regulation of green fluorescent protein-tagged forms of the human β_1 - and β_2 -adrenoceptors; comparisons with the unmodified receptors. <i>British Journal of Pharmacology</i> , 2000, 130, 1825-1832.	5.4	72
115	High-content assays for ligand regulation of G-protein-coupled receptors. <i>Drug Discovery Today</i> , 2003, 8, 579-585.	6.4	72
116	The sustainability of interactions between the orexin-1 receptor and β -arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. <i>Biochemical Journal</i> , 2005, 387, 573-584.	3.7	72
117	The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. <i>Biochemical Journal</i> , 2013, 452, 303-312.	3.7	72
118	G-proteins and G-protein subunits mediating cholinergic inhibition of N-type calcium currents in sympathetic neurons. <i>European Journal of Neuroscience</i> , 1998, 10, 1654-1666.	2.6	71
119	Robustness of G Proteins in Alzheimer's Disease: An Immunoblot Study. <i>Journal of Neurochemistry</i> , 1991, 57, 9-14.	3.9	70
120	Visualizing differences in ligand-induced β -arrestin-GFP interactions and trafficking between three recently characterized G-protein-coupled receptors. <i>Journal of Neurochemistry</i> , 2001, 77, 476-485.	3.9	70
121	G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. <i>Frontiers in Pharmacology</i> , 2015, 6, 41.	3.5	70
122	Palmitoylation Regulates Regulators of G-protein Signaling (RGS) 16 Function. <i>Journal of Biological Chemistry</i> , 2003, 278, 19301-19308.	3.4	69
123	Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster β_1B -adrenoceptor by ligands that act as inverse agonists. <i>Biochemical Journal</i> , 1997, 325, 733-739.	3.7	68
124	Agonist-Induced Endocytosis and Recycling of the Gonadotropin-Releasing Hormone Receptor: Effect of β -Arrestin on Internalization Kinetics. <i>Molecular Endocrinology</i> , 1998, 12, 1818-1829.	3.7	68
125	A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias. <i>Journal of Biological Chemistry</i> , 2016, 291, 18915-18931.	3.4	66
126	High-Affinity Interactions between Human β_1A -Adrenoceptor C-Terminal Splice Variants Produce Homo- and Heterodimers but Do Not Generate the β_1L -Adrenoceptor. <i>Molecular Pharmacology</i> , 2004, 66, 228-239.	2.3	65

#	ARTICLE	IF	CITATIONS
127	G protein-coupled receptors for free fatty acids. <i>Cellular Signalling</i> , 2006, 18, 1360-1365.	3.6	65
128	The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. <i>International Immunopharmacology</i> , 2011, 11, 1773-1779.	3.8	64
129	Agonist control of G-protein levels. <i>Trends in Pharmacological Sciences</i> , 1991, 12, 207-209.	8.7	63
130	Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1, Gi2, and Gi3. <i>Molecular Pharmacology</i> , 2007, 71, 1349-1359.	2.3	63
131	Comparative Analysis of the Efficacy of A1Adenosine Receptor Activation of Gi/o± G Proteins following Coexpression of Receptor and G Protein and Expression of A1Adenosine Receptor~Gi/o± Fusion Proteins. <i>Biochemistry</i> , 1999, 38, 2272-2278.	2.5	62
132	The Regulator of G Protein Signaling RGS4 Selectively Enhances Î±2A-Adreoreceptor Stimulation of the GTPase Activity of Go1± and Gi2±. <i>Journal of Biological Chemistry</i> , 2000, 275, 23693-23699.	3.4	62
133	Exploring the dynamics of regulation of G protein-coupled receptors using green fluorescent protein. <i>British Journal of Pharmacology</i> , 1999, 128, 501-510.	5.4	61
134	Multiple Roles for the C-terminal Tail of the Chemokine Scavenger D6. <i>Journal of Biological Chemistry</i> , 2008, 283, 7972-7982.	3.4	61
135	Evidence for Distinct Antagonist-Revealed Functional States of 5-Hydroxytryptamine_{2A} Receptor Homodimers. <i>Molecular Pharmacology</i> , 2009, 75, 1380-1391.	2.3	60
136	The Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 (FFA4/GPR120). <i>Journal of Biological Chemistry</i> , 2014, 289, 20345-20358.	3.4	60
137	Widespread distribution of Gq±/G11± detected immunologically by an antipeptide antiserum directed against the predicted C-terminal decapeptide. <i>FEBS Letters</i> , 1991, 287, 171-174.	2.8	59
138	Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. <i>British Journal of Pharmacology</i> , 2009, 158, 146-153.	5.4	59
139	Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via G13 and Î²-arrestin. <i>British Journal of Pharmacology</i> , 2011, 162, 733-748.	5.4	59
140	Agonist Occupation of an Î±2A-Adrenoreceptor-Gi1± Fusion Protein Results in Activation of Both Receptor-linked and Endogenous Gi Proteins. <i>Journal of Biological Chemistry</i> , 1998, 273, 10367-10375.	3.4	58
141	A Highly Conserved Glycine within Linker I and the Extreme C Terminus of G Protein Î± Subunits Interact Cooperatively in Switching G Protein-Coupled Receptor-to-Effector Specificity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 78-87.	2.5	58
142	Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 441-445.	2.8	58
143	Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands. <i>Molecular Pharmacology</i> , 2014, 86, 200-210.	2.3	58
144	Real Time Visualization of Agonist-mediated Redistribution and Internalization of a Green Fluorescent Protein-tagged Form of the Thyrotropin-releasing Hormone Receptor. <i>Journal of Biological Chemistry</i> , 1998, 273, 24000-24008.	3.4	57

#	ARTICLE	IF	CITATIONS
145	$\beta^2\beta^3$ dimers derived from G-proteins contribute different components of adrenergic inhibition of Ca^{2+} channels in rat sympathetic neurones. <i>Journal of Physiology</i> , 1999, 518, 23-36.	2.9	57
146	G Protein Coupling and Ligand Selectivity of the D_2 and D_3 Dopamine Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 319-330.	2.5	57
147	When simple agonism is not enough: Emerging modalities of GPCR ligands. <i>Molecular and Cellular Endocrinology</i> , 2011, 331, 241-247.	3.2	57
148	Concomitant Action of Structural Elements and Receptor Phosphorylation Determines Arrestin-3 Interaction with the Free Fatty Acid Receptor FFA4. <i>Journal of Biological Chemistry</i> , 2014, 289, 18451-18465.	3.4	57
149	Using the Flp-In, T-Rex System to Regulate GPCR Expression. <i>Methods in Molecular Biology</i> , 2011, 746, 21-37.	0.9	56
150	Developing Chemical Genetic Approaches to Explore G Protein-Coupled Receptor Function: Validation of the Use of a Receptor Activated Solely by Synthetic Ligand (RASSL). <i>Molecular Pharmacology</i> , 2011, 80, 1033-1046.	2.3	56
151	Regulation of Oligomeric Organization of the Serotonin 5-Hydroxytryptamine 2C (5-HT _{2C}) Receptor Observed by Spatial Intensity Distribution Analysis. <i>Journal of Biological Chemistry</i> , 2015, 290, 12844-12857.	3.4	55
152	Regional Distribution and Quantitative Measurement of the Phosphoinositidase C-Linked Guanine Nucleotide Binding Proteins G ₁₂ and G ₁₃ in Rat Brain. <i>Journal of Neurochemistry</i> , 1993, 61, 845-851.	3.9	54
153	Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 317-325.	8.7	54
154	Detection of the major pertussis toxin substrate of human leukocytes with antisera raised against synthetic peptides. <i>FEBS Letters</i> , 1986, 209, 352-356.	2.8	53
155	Identification of Two Distinct Isoforms of the Guanine Nucleotide Binding Protein Goin Neuroblastoma–Glioma Hybrid Cells: Independent Regulation During Cyclic AMP-Induced Differentiation. <i>Journal of Neurochemistry</i> , 1990, 55, 1890-1898.	3.9	53
156	The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35. <i>Molecular Pharmacology</i> , 2014, 85, 91-104.	2.3	53
157	Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Protein-Coupled Receptor 120. <i>Molecular Pharmacology</i> , 2016, 89, 505-520.	2.3	53
158	GTP-Binding proteins in brain and neutrophil are tethered to the plasma membrane via their amino termini. <i>Biochemical and Biophysical Research Communications</i> , 1987, 148, 1398-1405.	2.1	52
159	Ligand Regulation of the Quaternary Organization of Cell Surface M3 Muscarinic Acetylcholine Receptors Analyzed by Fluorescence Resonance Energy Transfer (FRET) Imaging and Homogeneous Time-resolved FRET. <i>Journal of Biological Chemistry</i> , 2010, 285, 23318-23330.	3.4	52
160	Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 982-992.	6.4	52
161	Chemogenetics defines receptor-mediated functions of short chain free fatty acids. <i>Nature Chemical Biology</i> , 2019, 15, 489-498.	8.0	52
162	Measurement of agonist-induced guanine nucleotide turnover by the G-protein G_{i1} when constrained within an α_2A -adrenoceptor- G_{i1} fusion protein. <i>Biochemical Journal</i> , 1997, 325, 17-21.	3.7	51

#	ARTICLE	IF	CITATIONS
163	Changes in the guanine nucleotide-binding proteins, Gi and Go, during differentiation of 3T3-L1 cells. <i>FEBS Letters</i> , 1986, 199, 103-106.	2.8	50
164	SELECTIVE DEFICIENCY OF GUANINE NUCLEOTIDE-BINDING PROTEIN Go IN TWO DOPAMINE-RESISTANT PITUITARY TUMORS. <i>Endocrinology</i> , 1988, 122, 1176-1178.	2.8	50
165	Selective Interactions between Helix VIII of the Human μ -Opioid Receptors and the C Terminus of Periplakin Disrupt G Protein Activation. <i>Journal of Biological Chemistry</i> , 2003, 278, 33400-33407.	3.4	50
166	Identification of a Novel Site within G Protein β Subunits Important for Specificity of Receptor-G Protein Interaction. <i>Molecular Pharmacology</i> , 2004, 66, 250-259.	2.3	50
167	Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Methylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6624-6628.	6.4	50
168	Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84. <i>Scientific Reports</i> , 2017, 7, 17953.	3.3	50
169	Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands. <i>Journal of Biological Chemistry</i> , 2016, 291, 303-317.	3.4	49
170	Rescue of Functional Interactions between the β 2-Adrenoreceptor and Acylation-resistant Forms of G β 1 γ by Expressing the Proteins from Chimeric Open Reading Frames. <i>Journal of Biological Chemistry</i> , 1997, 272, 24673-24678.	3.4	48
171	Tissue-specific regulation of GTP-binding protein and muscarinic acetylcholine receptor levels during cardiac development. <i>Biochemistry</i> , 1987, 26, 4876-4884.	2.5	47
172	Morphine Desensitization, Internalization, and Down-Regulation of the μ Opioid Receptor Is Facilitated by Serotonin 5-Hydroxytryptamine _{2A} Receptor Coactivation. <i>Molecular Pharmacology</i> , 2008, 74, 1278-1291.	2.3	47
173	Experimental Challenges to Targeting Poorly Characterized GPCRs: Uncovering the Therapeutic Potential for Free Fatty Acid Receptors. <i>Advances in Pharmacology</i> , 2011, 62, 175-218.	2.0	47
174	A general method to quantify ligand-driven oligomerization from fluorescence-based images. <i>Nature Methods</i> , 2019, 16, 493-496.	19.0	47
175	Kinetics of Ternary Complex Formation with Fusion Proteins Composed of the A1-Adenosine Receptor and G Protein β -Subunits. <i>Journal of Biological Chemistry</i> , 1999, 274, 30571-30579.	3.4	46
176	Palmitoylation Regulates Regulator of G-protein Signaling (RGS) 16 Function. <i>Journal of Biological Chemistry</i> , 2003, 278, 19309-19316.	3.4	46
177	Analysis of inverse agonism at the δ opioid receptor after expression in Rat 1 fibroblasts. <i>Biochemical Journal</i> , 1996, 315, 227-234.	3.7	45
178	Coordinated Agonist Regulation of Receptor and G Protein Palmitoylation and Functional Rescue of Palmitoylation-deficient Mutants of the G Protein G β 1 γ following Fusion to the β 1b-Adrenoreceptor. <i>Journal of Biological Chemistry</i> , 2001, 276, 35883-35890.	3.4	45
179	Human D2 and D4 dopamine receptors couple through β 3 G-protein subunits to inwardly rectifying K ⁺ channels (GIRK1) in a <i>Xenopus</i> oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively. <i>Neuropharmacology</i> , 1998, 37, 983-987.	4.1	44
180	Distribution and relative levels of expression of the phosphoinositide-C-linked G-proteins Gq β and G11 β : Absence of G11 β in human platelets and haemopoietically derived cell lines. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1993, 1179, 208-212.	4.1	43

#	ARTICLE	IF	CITATIONS
181	Regulation of Spontaneous Activity of the μ -Opioid Receptor: Studies of Inverse Agonism in Intact Cells. <i>Journal of Neurochemistry</i> , 1997, 69, 2115-2122.	3.9	43
182	GTP analogues cause release of the alpha subunit of the GTP binding protein, G α , from the plasma membrane of NG108-15 cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 152, 243-251.	2.1	42
183	Multiple defects occur in the guanine nucleotide regulatory protein system in liver plasma membranes of obese (fa/fa) but not lean (Fa/Fa) Zucker rats: Loss of functional G β and abnormal G γ function. <i>Cellular Signalling</i> , 1989, 1, 9-22.	3.6	42
184	Agonist-induced Internalization of the G Protein G β 11 and Thyrotropin-releasing Hormone Receptors Proceed on Different Time Scales. <i>Journal of Biological Chemistry</i> , 1998, 273, 21699-21707.	3.4	42
185	Agonists activate G β 11 or G β 2 fused to the human mu opioid receptor differently. <i>Journal of Neurochemistry</i> , 2002, 81, 1372-1382.	3.9	42
186	Src-mediated RGS16 Tyrosine Phosphorylation Promotes RGS16 Stability. <i>Journal of Biological Chemistry</i> , 2003, 278, 16107-16116.	3.4	42
187	β -Arrestin-Dependent Spontaneous β 1a-Adrenoceptor Endocytosis Causes Intracellular Transport of β -Blockers via Recycling Compartments. <i>Molecular Pharmacology</i> , 2005, 67, 992-1004.	2.3	42
188	Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. <i>BMC Bioinformatics</i> , 2007, 8, 177.	2.6	42
189	Therapeutic Opportunities and Challenges in Targeting the Orphan G Protein-Coupled Receptor GPR35. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 801-812.	4.9	42
190	Altered G-protein expression and adenylate cyclase activity in platelets of non-insulin-dependent diabetic (NIDDM) male subjects. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1991, 1096, 127-133.	3.8	41
191	Wortmannin-sensitive Activation of p70 by Endogenous and Heterologously Expressed G-coupled Receptors. <i>Journal of Biological Chemistry</i> , 1996, 271, 8537-8540.	3.4	41
192	Selective interactions of μ -opioid receptors with pertussis toxin-sensitive G proteins: involvement of the third intracellular loop and the c-terminal tail in coupling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1997, 1359, 263-274.	4.1	41
193	Visualization of Agonist-induced Association and Trafficking of Green Fluorescent Protein-tagged Forms of Both β -Arrestin-1 and the Thyrotropin-releasing Hormone Receptor-1. <i>Journal of Biological Chemistry</i> , 1999, 274, 23263-23269.	3.4	41
194	Functional Homomers and Heteromers of Dopamine D β 2L and D β 3 Receptors Co-exist at the Cell Surface. <i>Journal of Biological Chemistry</i> , 2012, 287, 8864-8878.	3.4	41
195	The human muscarinic M1 acetylcholine receptor, when expressed in CHO cells, activates and downregulates both G β 11 and G β 11 equally and non-selectively. <i>FEBS Letters</i> , 1993, 324, 241-245.	2.8	40
196	Agonist regulation of adenylate cyclase activity in neuroblastoma Å glioma hybrid NG108-15 cells transfected to co-express adenylate cyclase type II and the β 2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptor-mediated stimulation of adenylate cyclase activity. <i>Biochemical Journal</i> , 1996, 318, 1033-1039.	3.7	40
197	Functional Complementation and the Analysis of Opioid Receptor Homodimerization. <i>Molecular Pharmacology</i> , 2005, 68, 905-915.	2.3	40
198	Mutations of β -arrestin 2 that limit self-association also interfere with interactions with the β 2-adrenoceptor and the ERK1/2 MAPKs: implications for β 2-adrenoceptor signalling via the ERK1/2 MAPKs. <i>Biochemical Journal</i> , 2008, 413, 51-60.	3.7	40

#	ARTICLE	IF	CITATIONS
199	Antagonists of GPR35 Display High Species Ortholog Selectivity and Varying Modes of Action. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 683-695.	2.5	40
200	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4849-4858.	6.4	40
201	The human $\hat{\nu}$ opioid receptor activates G_{i1} more efficiently than G_{o1} . <i>Journal of Neurochemistry</i> , 2001, 76, 1805-1813.	3.9	39
202	G protein-coupled receptor modulation with pepducins: moving closer to the clinic. <i>Annals of the New York Academy of Sciences</i> , 2011, 1226, 34-49.	3.8	39
203	The Dynamics of Formation and Action of the Ternary Complex Revealed in Living Cells Using a G-protein-gated K^+ Channel as a Biosensor. <i>Journal of Biological Chemistry</i> , 2003, 278, 10851-10858.	3.4	38
204	Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric $\hat{\nu}2$ -adrenoceptor. <i>Cellular Signalling</i> , 2007, 19, 1928-1938.	3.6	38
205	Novel Role for Proteinase-activated Receptor 2 (PAR2) in Membrane Trafficking of Proteinase-activated Receptor 4 (PAR4). <i>Journal of Biological Chemistry</i> , 2012, 287, 16656-16669.	3.4	38
206	Immunochemical and electrophoretic characterization of the major pertussis toxin substrate of the RAW264 macrophage cell line. <i>Biochemistry</i> , 1988, 27, 2040-2046.	2.5	37
207	Melatonin Receptors Couple Through a Cholera Toxin-Sensitive Mechanism to Inhibit Cyclic AMP in the Ovine Pituitary. <i>Journal of Neuroendocrinology</i> , 1995, 7, 361-369.	2.6	37
208	The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. <i>Cellular Signalling</i> , 1996, 8, 87-95.	3.6	37
209	Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs. <i>Journal of Biological Chemistry</i> , 2016, 291, 13132-13146.	3.4	37
210	The emerging pharmacology and function of GPR35 in the nervous system. <i>Neuropharmacology</i> , 2017, 113, 661-671.	4.1	37
211	Analysis of the C-Terminal Tail of the Rat Thyrotropin-Releasing Hormone Receptor-1 in Interactions and Cointernalization with $\hat{\nu}2$ -Arrestin 1-Green Fluorescent Protein. <i>Molecular Pharmacology</i> , 2001, 59, 375-385.	2.3	37
212	Degradation of G_{i1}/G_{q1} Is Accelerated by Agonist Occupancy of $\hat{\nu}1A/D$, $\hat{\nu}1B$, and $\hat{\nu}1C$ Adrenergic Receptors. <i>Journal of Biological Chemistry</i> , 1995, 270, 17196-17203.	3.4	36
213	Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant $\hat{\nu}2$ -Adrenoceptor-Green Fluorescent Protein Fusion Proteins. <i>Molecular Pharmacology</i> , 1999, 56, 1182-1191.	2.3	36
214	Visualization of distinct patterns of subcellular redistribution of the thyrotropin-releasing hormone receptor-1 and G_{q1}/G_{i1} induced by agonist stimulation. <i>Biochemical Journal</i> , 1999, 340, 529-538.	3.7	36
215	Opioid Receptors and Their Interacting Proteins. <i>NeuroMolecular Medicine</i> , 2005, 7, 051-060.	3.4	36
216	Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective $\hat{\nu}1b$ -adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers. <i>Biochemical Journal</i> , 2009, 417, 161-172.	3.7	36

#	ARTICLE	IF	CITATIONS
217	The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction. <i>Current Drug Targets</i> , 2012, 13, 80-102.	2.1	36
218	Alterations in the activity of adenylate cyclase and high affinity GTPase in Alzheimer's disease. <i>Brain Research</i> , 1993, 622, 35-42.	2.2	35
219	Agonist-induced Transfer of the alpha Subunits of the Guanine-nucleotide-binding Regulatory Proteins Gq and G11, and of Muscarinic m1 Acetylcholine Receptors from Plasma Membranes to a Light-vesicular Membrane Fraction. <i>FEBS Journal</i> , 1994, 224, 455-462.	0.2	35
220	Up-regulation of a constitutively active form of the β_2 -adrenoceptor by sustained treatment with inverse agonists but not antagonists. <i>FEBS Letters</i> , 1996, 399, 108-112.	2.8	35
221	Periplakin Interferes with G Protein Activation by the Melanin-concentrating Hormone Receptor-1 by Binding to the Proximal Segment of the Receptor C-terminal Tail. <i>Journal of Biological Chemistry</i> , 2005, 280, 8208-8220.	3.4	35
222	Growth Hormone Secretagogues and Growth Hormone Releasing Peptides Act As Orthosteric Super-Agonists but Not Allosteric Regulators for Activation of the G Protein G_{i1} by the Ghrelin Receptor. <i>Molecular Pharmacology</i> , 2009, 76, 802-811.	2.3	35
223	High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. <i>Biochemical Journal</i> , 2010, 432, 21-35.	3.7	35
224	G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. <i>British Journal of Nutrition</i> , 2014, 111, S3-S7.	2.3	35
225	Evidence for the Existence of a CXCL17 Receptor Distinct from GPR35. <i>Journal of Immunology</i> , 2018, 201, 714-724.	0.8	35
226	Mitogenic signalling by μ opioid receptors expressed in Rat-1 fibroblasts involves activation of the p70s6k/p85s6k S6 kinase. <i>Biochemical Journal</i> , 1997, 325, 217-222.	3.7	34
227	Measurement of agonist efficacy using an β_2 -adrenoceptor-Gi1 fusion protein. <i>FEBS Letters</i> , 1997, 419, 141-146.	2.8	34
228	Modulation of Relative Intrinsic Activity of Agonists at the α -2A Adrenoceptor by Mutation of Residue 351 of G Protein Gi1. <i>Molecular Pharmacology</i> , 1999, 55, 195-201.	2.3	34
229	Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling. <i>FASEB Journal</i> , 2002, 16, 1185-1194.	0.5	34
230	Ligand-induced internalization of the orexin OX_1 and cannabinoid CB_1 receptors assessed via N-terminal SNAP and CLIP tagging. <i>British Journal of Pharmacology</i> , 2011, 162, 1439-1452.	5.4	34
231	Dietary fibers inhibit obesity in mice, but host responses in the cecum and liver appear unrelated to fiber-specific changes in cecal bacterial taxonomic composition. <i>Scientific Reports</i> , 2018, 8, 15566.	3.3	34
232	CypHer 5: A Generic Approach for Measuring the Activation and Trafficking of G Protein-Coupled Receptors in Live Cells. <i>Assay and Drug Development Technologies</i> , 2003, 1, 251-259.	1.2	33
233	Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein coupled receptors. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 167-180.	3.7	33
234	Eukaryotic Translation Initiation Factor 3, Subunit a, Regulates the Extracellular Signal-Regulated Kinase Pathway. <i>Molecular and Cellular Biology</i> , 2012, 32, 88-95.	2.3	33

#	ARTICLE	IF	CITATIONS
235	Indomethacin Treatment Prevents High Fat Diet-induced Obesity and Insulin Resistance but Not Glucose Intolerance in C57BL/6j Mice. <i>Journal of Biological Chemistry</i> , 2014, 289, 16032-16045.	3.4	33
236	Metabolic and inflammatory functions of short-chain fatty acid receptors. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 16, 1-9.	1.4	33
237	Effective Information Transfer from the $\hat{I}\pm 1b$ -Adrenoceptor to $G\hat{I}\pm 11$ Requires Both \hat{I}^2/\hat{I}^3 Interactions and an Aromatic Group Four Amino Acids from the C Terminus of the G Protein. <i>Journal of Biological Chemistry</i> , 2002, 277, 25707-25714.	3.4	32
238	Lentivirus-mediated Reprogramming of Somatic Cells in the Absence of Transgenic Transcription Factors. <i>Molecular Therapy</i> , 2010, 18, 2139-2145.	8.2	32
239	High-Throughput Identification and Characterization of Novel, Species-selective GPR35 Agonists. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 568-578.	2.5	32
240	Development and Characterization of a Fluorescent Tracer for the Free Fatty Acid Receptor 2 (FFA2/GPR43). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5638-5645.	6.4	32
241	Guanine nucleotide regulation of the pertussis and cholera toxin substrates of rat glioma C6 BU1 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1987, 929, 197-202.	4.1	31
242	Guanine nucleotide regulatory protein levels and function in spontaneously hypertensive rat vascular smooth-muscle cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992, 1136, 290-296.	4.1	31
243	Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins. <i>Biochemical Journal</i> , 1999, 342, 457-463.	3.7	31
244	The orexin OX1 receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands. <i>Biochemical Journal</i> , 2011, 439, 171-183.	3.7	31
245	Spatial intensity distribution analysis quantifies the extent and regulation of homodimerization of the secretin receptor. <i>Biochemical Journal</i> , 2017, 474, 1879-1895.	3.7	31
246	Resolution of Inverse Agonist-Induced Up-Regulation from Constitutive Activity of Mutants of the $\hat{I}\pm 1b$ -Adrenoceptor. <i>Molecular Pharmacology</i> , 2000, 58, 438-448.	2.3	30
247	Multiple pertussis toxin-sensitive G-proteins can couple receptors to GIRK channels in rat sympathetic neurons when expressed heterologously, but only native G_i -proteins do so in situ. <i>European Journal of Neuroscience</i> , 2001, 14, 283-292.	2.6	30
248	The Specificity and Molecular Basis of $\hat{I}\pm 1$ -Adrenoceptor and CXCR Chemokine Receptor Dimerization. <i>Journal of Molecular Neuroscience</i> , 2005, 26, 161-168.	2.3	30
249	Interaction of Neurochondrin with the Melanin-concentrating Hormone Receptor 1 Interferes with G Protein-coupled Signal Transduction but Not Agonist-mediated Internalization. <i>Journal of Biological Chemistry</i> , 2006, 281, 32496-32507.	3.4	30
250	Roundabout 1 exists predominantly as a basal dimeric complex and this is unaffected by binding of the ligand Slit2. <i>Biochemical Journal</i> , 2014, 461, 61-73.	3.7	30
251	A Molecular Mechanism for Sequential Activation of a G Protein-Coupled Receptor. <i>Cell Chemical Biology</i> , 2016, 23, 392-403.	5.2	30
252	Genome Editing Provides New Insights into Receptor-Controlled Signalling Pathways. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 481-493.	8.7	30

#	ARTICLE	IF	CITATIONS
253	Context-Dependent Signaling of CXC Chemokine Receptor 4 and Atypical Chemokine Receptor 3. <i>Molecular Pharmacology</i> , 2019, 96, 778-793.	2.3	30
254	Identification of both Gi 2 and a novel, immunologically distinct, form of Go in rat myometrial membranes. <i>FEBS Letters</i> , 1989, 244, 411-416.	2.8	29
255	Differential capacities of the RGS1, RGS16 and RGS-GAIP regulators of G protein signaling to enhance Î±2A-adrenoreceptor agonist-stimulated GTPase activity of Go1Î±. <i>Journal of Neurochemistry</i> , 2001, 78, 797-806.	3.9	29
256	Measurement of Agonist-Dependent and -Independent Signal Initiation of Î±1b-Adrenoceptor Mutants by Direct Analysis of Guanine Nucleotide Exchange on the G Protein GÎ±11. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 1080-1088.	2.5	29
257	Structural and biophysical characterisation of G protein-coupled receptor ligand binding using resonance energy transfer and fluorescent labelling techniques. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2014, 1838, 3-14.	2.6	29
258	Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4. <i>Molecular Pharmacology</i> , 2017, 91, 630-641.	2.3	29
259	Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9534-9550.	6.4	29
260	Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13526-13545.	6.4	29
261	Minireview: The Effects of Species Ortholog and SNP Variation on Receptors for Free Fatty Acids. <i>Molecular Endocrinology</i> , 2013, 27, 1177-1187.	3.7	28
262	G-proteins in experimental hypertension: a study of spontaneously hypertensive rat myocardial and renal cortical plasma membranes. <i>Journal of Hypertension</i> , 1993, 11, 365-372.	0.5	27
263	Quantitative stoichiometry of the proteins of the stimulatory arm of the adenylyl cyclase cascade in neuroblastoma x glioma hybrid, NG108-15 cells. <i>FEBS Journal</i> , 1994, 219, 135-143.	0.2	27
264	Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41). <i>Handbook of Experimental Pharmacology</i> , 2016, 236, 17-32.	1.8	27
265	Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance.. <i>FASEB Journal</i> , 2017, 31, 2195-2209.	0.5	27
266	Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84. <i>British Journal of Pharmacology</i> , 2022, 179, 3529-3541.	5.4	27
267	The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 14-25.	2.1	26
268	The Î±2B adrenergic receptor of undifferentiated neuroblastoma - glioma hybrid NG108-15 cells, interacts directly with the guanine nucleotide binding protein, Gi2. <i>FEBS Letters</i> , 1990, 269, 430-434.	2.8	25
269	Enhanced Detection of Receptor Constitutive Activity in the Presence of Regulators of G Protein Signaling: Applications to the Detection and Analysis of Inverse Agonists and Low-Efficacy Partial Agonists. <i>Molecular Pharmacology</i> , 2002, 61, 1211-1221.	2.3	25
270	Elevated levels of the guanine nucleotide binding protein, Go , are associated with differentiation of neuroblastoma - glioma hybrid cells. <i>FEBS Letters</i> , 1989, 244, 113-118.	2.8	24

#	ARTICLE	IF	CITATIONS
271	S 14506: novel receptor coupling at 5-HT1A receptors. <i>Neuropharmacology</i> , 2001, 40, 334-344.	4.1	24
272	Spatial Intensity Distribution Analysis: Studies of G Protein-Coupled Receptor Oligomerisation. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 175-186.	8.7	24
273	The Orphan Receptor GPR35 Contributes to Angiotensin II-Induced Hypertension and Cardiac Dysfunction in Mice. <i>American Journal of Hypertension</i> , 2018, 31, 1049-1058.	2.0	24
274	A Cysteine-3 to Serine Mutation of the G-Protein Gi1 Abrogates Functional Activation by the β 2-Adrenoceptor but Not Interactions with the β 2 γ 3 Complex. <i>Biochemistry</i> , 1997, 36, 10620-10629.	2.5	23
275	Kinetic analysis of the internalization and recycling of [3H]TRH and C-terminal truncations of the long isoform of the rat thyrotropin-releasing hormone receptor-1. <i>Biochemical Journal</i> , 2000, 346, 711-718.	3.7	23
276	μ / κ Opioid Receptor Functional Interaction: Insight Using Receptor-G Protein Fusions. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 683-690.	2.5	23
277	Novel pharmacological applications of G-protein-coupled receptor G protein fusions. <i>Current Opinion in Pharmacology</i> , 2007, 7, 521-526.	3.5	23
278	G-Protein-Coupled Receptor 35 Mediates Human Saphenous Vein Vascular Smooth Muscle Cell Migration and Endothelial Cell Proliferation. <i>Journal of Vascular Research</i> , 2015, 52, 383-395.	1.4	23
279	Analysis of Human Dopamine D3 Receptor Quaternary Structure. <i>Journal of Biological Chemistry</i> , 2015, 290, 15146-15162.	3.4	23
280	Receptor selectivity between the G proteins G β 12 and G β 13 is defined by a single leucine-to-isoleucine variation. <i>FASEB Journal</i> , 2019, 33, 5005-5017.	0.5	23
281	Differential distribution of signal-transducing G-proteins in retina. <i>Brain Research</i> , 1987, 423, 237-246.	2.2	22
282	Immunological identification of the β 13 subunit of G13, a novel guanine nucleotide binding protein. <i>FEBS Letters</i> , 1992, 297, 186-188.	2.8	22
283	Signal Sorting by G-Protein-Linked Receptors. <i>Advances in Pharmacology</i> , 1995, 32, 1-29.	2.0	22
284	New Aspects of G-Protein-Coupled Receptor Signalling and Regulation. <i>Trends in Endocrinology and Metabolism</i> , 1998, 9, 13-19.	7.1	22
285	G protein-coupled receptors not currently in the spotlight: free fatty acid receptor 2 and GPR35. <i>British Journal of Pharmacology</i> , 2018, 175, 2543-2553.	5.4	22
286	Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor. <i>Journal of Biological Chemistry</i> , 2022, 298, 101655.	3.4	22
287	Efficacy of inverse agonists in cells overexpressing a constitutively active β 2-adrenoceptor and type II adenylyl cyclase. <i>British Journal of Pharmacology</i> , 1998, 123, 335-343.	5.4	21
288	Selective Activation of a Chimeric Gi1/GsG Protein β 13 Subunit by the Human IP Prostanoid Receptor: Analysis Using Agonist Stimulation of High Affinity GTPase Activity and [35S]Guanosine-5'-O-(3-thio)triphosphate Binding. <i>Molecular Pharmacology</i> , 1998, 54, 249-257.	2.3	21

#	ARTICLE	IF	CITATIONS
289	Thyrotropin-releasing hormone-induced depletion of Gq $\hat{\pm}$ /G11 $\hat{\pm}$ proteins from detergent-insensitive membrane domains. <i>FEBS Letters</i> , 1999, 464, 35-40.	2.8	21
290	Action of <i>Pasteurella multocida</i> toxin on G $\hat{\pm}$ q is persistent and independent of interaction with G-protein-coupled receptors. <i>Cellular Signalling</i> , 2007, 19, 2174-2182.	3.6	21
291	Intramolecular Fluorescence Resonance Energy Transfer (FRET) Sensors of the Orexin OX1 and OX2 Receptors Identify Slow Kinetics of Agonist Activation. <i>Journal of Biological Chemistry</i> , 2012, 287, 14937-14949.	3.4	21
292	A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias. <i>Scientific Reports</i> , 2017, 7, 13741.	3.3	21
293	Chemogenetics defines a short-chain fatty acid receptor gut-brain axis. <i>ELife</i> , 2022, 11, .	6.0	21
294	G-proteins in essential hypertension: a study of human platelet plasma membranes. <i>Journal of Hypertension</i> , 1993, 11, 543-550.	0.5	20
295	Interaction of the G-protein G11 $\hat{\pm}$ with receptors and phosphoinositidase C:. <i>FEBS Letters</i> , 1997, 407, 257-260.	2.8	20
296	Generation and Analysis of Constitutively Active and Physically Destabilized Mutants of the Human $\hat{\pm}$ 1-Adrenoceptor. <i>Molecular Pharmacology</i> , 2002, 62, 747-755.	2.3	20
297	A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptor. <i>BMC Biochemistry</i> , 2004, 5, 12.	4.4	20
298	Analysis of endogenous S1P and LPA receptor expression in CHO-K1 cells. <i>Gene</i> , 2005, 350, 59-63.	2.2	20
299	Carvedilol-induced antagonism of angiotensin II: a matter of $\hat{\pm}$ 1-adrenoceptor blockade. <i>Journal of Hypertension</i> , 2006, 24, 1355-1363.	0.5	20
300	Antibodies that identify only the active conformation of G_i-family G protein $\hat{\pm}$ subunits. <i>FASEB Journal</i> , 2008, 22, 1924-1932.	0.5	20
301	GPCR Oligomerization and Receptor Trafficking. <i>Methods in Enzymology</i> , 2013, 521, 69-90.	1.0	20
302	The Molecular Basis of Oligomeric Organization of the Human M₃ Muscarinic Acetylcholine Receptor. <i>Molecular Pharmacology</i> , 2015, 87, 936-953.	2.3	20
303	Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2841-2846.	6.4	20
304	On-target and off-target effects of novel orthosteric and allosteric activators of GPR84. <i>Scientific Reports</i> , 2019, 9, 1861.	3.3	20
305	Pathophysiological regulation of lung function by the free fatty acid receptor FFA4. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	20
306	G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic <i>Bacteroides fragilis</i> . <i>Communications Biology</i> , 2021, 4, 585.	4.4	20

#	ARTICLE	IF	CITATIONS
307	Biphasic regulation of adenylate cyclase by cholera toxin in neuroblastoma Å— glioma hybrid cells is due to the activation and subsequent loss of the Î± subunit of the stimulatory GTP binding proteins (Gs). <i>Cellular Signalling</i> , 1990, 2, 139-151.	3.6	19
308	Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor. <i>British Journal of Pharmacology</i> , 2001, 133, 315-323.	5.4	19
309	Î±Opioid receptors exhibit high efficiency when activating trimeric G proteins in membrane domains. <i>Journal of Neurochemistry</i> , 2003, 85, 34-49.	3.9	19
310	Selectivity and functional consequences of interactions of family A G proteinâ€coupled receptors with neurochondrin and periplakin. <i>Journal of Neurochemistry</i> , 2009, 109, 182-192.	3.9	19
311	The use of specific antibodies to identify and quantify guanine nucleotide-binding proteins. <i>Biochemical Society Transactions</i> , 1987, 15, 42-45.	3.4	18
312	A Key Serine for the GTPase-Activating Protein Function of Regulator of G Protein Signaling Proteins Is Not a General Target for 14-3-3 Interactions. <i>Molecular Pharmacology</i> , 2005, 68, 1821-1830.	2.3	18
313	Expression of gsÎ±, connexin-43, connexin-26, and EP1, 3, and 4 receptors in myometrium of prelabor singleton versus multiple gestations and the effects of mechanical stretch and steroids on gsÎ±. <i>Journal of the Society for Gynecologic Investigation</i> , 2002, 9, 299-307.	1.7	18
314	Selective phosphorylation of threonine residues defines GPR84â€™arrestin interactions of biased ligands. <i>Journal of Biological Chemistry</i> , 2022, 298, 101932.	3.4	18
315	Chronic exposure of rat glioma C6 cells to cholera toxin induces loss of the Î±-subunit of the stimulatory guanine nucleotide-binding protein (Gs). <i>European Journal of Pharmacology</i> , 1990, 188, 203-209.	2.6	17
316	Involvement of G-protein Î±il subunits in activation of G-protein gated inward rectifying K+ channels (GIRK1) by human NPY1 receptors. <i>British Journal of Pharmacology</i> , 1995, 116, 2346-2348.	5.4	17
317	Functional analysis of a human A1adenosine receptor/green fluorescent protein/Gi1Î± fusion protein following stable expression in CHO cells. <i>FEBS Letters</i> , 1999, 462, 61-65.	2.8	17
318	Dominant Portion of Thyrotropin-Releasing Hormone Receptor Is Excluded from Lipid Domains. Detergent-Resistant and Detergent-Sensitive Pools of TRH Receptor and Gq1/G11Î± Protein. <i>Journal of Biochemistry</i> , 2005, 138, 111-125.	1.7	17
319	Regulation of cardiovascular remodeling by the counter-regulatory axis of the reninâ€™angiotensin system. <i>Future Cardiology</i> , 2013, 9, 23-38.	1.2	17
320	A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization. <i>Scientific Reports</i> , 2017, 7, 2134.	3.3	17
321	Ligand Rescue of Constitutively Active Mutant Receptors. <i>NeuroSignals</i> , 2002, 11, 29-33.	0.9	16
322	Expression of the Human Î²2-Adrenoceptor in NCB20 Cells Results in Agonist Activation of Adenylyl Cyclase and Agonist-Mediated Selective Down-Regulation of GsÎ±. <i>Journal of Neurochemistry</i> , 2002, 65, 545-553.	3.9	16
323	Mechanism of Action of Gqto Inhibit GÎ²Î³ Modulation of CaV2.2 Calcium Channels: Probed by the Use of Receptor-GÎ± Tandems. <i>Molecular Pharmacology</i> , 2003, 63, 832-843.	2.3	16
324	Succinct synthesis of saturated hydroxy fatty acids and <i>in vitro</i> evaluation of all hydroxylauric acids on FFA1, FFA4 and GPR84. <i>MedChemComm</i> , 2017, 8, 1360-1365.	3.4	16

#	ARTICLE	IF	CITATIONS
325	Guanine nucleotide regulatory proteins in insulin's action and in diabetes. <i>Biochemical Society Transactions</i> , 1989, 17, 627-629.	3.4	15
326	Concerted stimulation and deactivation of pertussis toxin-sensitive G α f proteins by chimeric G α f protein-coupled receptor-regulator of G α f protein signaling 4 fusion proteins: analysis of the contribution of palmitoylated cysteine residues to the GAP activity. <i>Journal of Neurochemistry</i> , 2003, 85, 1289-1298.	3.9	15
327	Activation of an α 2A-adrenoceptor-Gi1 fusion protein dynamically regulates the palmitoylation status of the G protein but not of the receptor. <i>Biochemical Journal</i> , 2005, 385, 197-206.	3.7	15
328	MicroRNA regulation of endothelial homeostasis and commitment—implications for vascular regeneration strategies using stem cell therapies. <i>Free Radical Biology and Medicine</i> , 2013, 64, 52-60.	2.9	15
329	Muscarinic receptor oligomerization. <i>Neuropharmacology</i> , 2018, 136, 401-410.	4.1	15
330	Design, Synthesis, and Evaluation of a Diazirine Photoaffinity Probe for Ligand-Based Receptor Capture Targeting G Protein-Coupled Receptors. <i>Molecular Pharmacology</i> , 2019, 95, 196-209.	2.3	15
331	Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t. <i>Journal of Biological Chemistry</i> , 2021, 296, 100139.	3.4	15
332	Differences in the Signaling Pathways of α 1A- and α 1B-Adrenoceptors Are Related to Different Endosomal Targeting. <i>PLoS ONE</i> , 2013, 8, e64996.	2.5	15
333	Tissue distribution and subcellular location of guanine nucleotide binding proteins: Implications for cellular signalling. <i>Cellular Signalling</i> , 1989, 1, 411-419.	3.6	14
334	A constitutively active mutant of the α 1B-adrenergic receptor can cause greater agonist-dependent down-regulation of the G-proteins Gq and G11 than the wild-type receptor. <i>Biochemical Journal</i> , 1996, 320, 79-86.	3.7	14
335	Loss of activation of Gs but not Gi following expression of an α 2A-adrenoceptor-Gi1 fusion protein. <i>FEBS Letters</i> , 1998, 436, 46-50.	2.8	14
336	Construction and analysis of function of G protein-coupled receptor-G protein fusion proteins. <i>Methods in Enzymology</i> , 2002, 343, 260-273.	1.0	14
337	Long-term agonist stimulation of IP prostanoid receptor depletes the cognate Gs protein in membrane domains but does not change the receptor level. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2004, 1691, 51-65.	4.1	14
338	Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. <i>Biochemical Society Transactions</i> , 2010, 38, 1058-1061.	3.4	14
339	MicroRNAs regulating cell pluripotency and vascular differentiation. <i>Vascular Pharmacology</i> , 2011, 55, 69-78.	2.1	14
340	Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins. <i>Biochemical Journal</i> , 1999, 342, 457.	3.7	14
341	Stimulus-response coupling in FMLP-stimulated U937 monocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1990, 1051, 71-77.	4.1	13
342	Agonist regulation of cellular levels of the stimulatory guanine nucleotide-binding protein, Gs, in wild type and transfected neuroblastoma-glioma hybrid NG108-15 cells. <i>Biochemical Society Transactions</i> , 1993, 21, 432-435.	3.4	13

#	ARTICLE	IF	CITATIONS
343	Equivalent regulation of wild type and an epitope-tagged variant of Gs α by the IP prostanoid receptor following expression in neuroblastoma Å— glioma hybrid, NG108-15, cells. FEBS Letters, 1994, 353, 231-234.	2.8	13
344	An Asp79Asn mutation of the Î±2A-adrenoceptor interferes equally with agonist activation of individual Gi1±-family G protein subtypes. FEBS Letters, 1999, 462, 459-463.	2.8	13
345	Ligand Specific Up-Regulation of a Renilla reniformis Luciferase-Tagged, Structurally Unstable Muscarinic M3 Chimeric G Protein-Coupled Receptor. Molecular Pharmacology, 2003, 64, 1474-1484.	2.3	13
346	Autoimmune Disease-Associated Histamine Receptor H1 Alleles Exhibit Differential Protein Trafficking and Cell Surface Expression. Journal of Immunology, 2008, 180, 7471-7479.	0.8	13
347	Profiling of transcriptional and epigenetic changes during directed endothelial differentiation of human embryonic stem cells identifies FOXA2 as a marker of early mesoderm commitment. Stem Cell Research and Therapy, 2013, 4, 36.	5.5	13
348	Differential manipulation of arrestin-3 binding to basal and agonist-activated G protein-coupled receptors. Cellular Signalling, 2017, 36, 98-107.	3.6	13
349	The Use of Receptor G-Protein Fusion Proteins for the Study of Ligand Activity. Receptors and Channels, 2002, 8, 309-317.	1.1	13
350	Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13
351	The use of anti-peptide antisera to probe interactions between receptors and guanine nucleotide binding proteins. Biochemical Society Transactions, 1988, 16, 434-437.	3.4	12
352	[21] Specificity and functional applications of antipeptide antisera which identify G-protein Î± subunits. Methods in Enzymology, 1994, 237, 268-283.	1.0	12
353	Cold-induced reduction in Gi1± proteins in brown adipose tissue. Effects on the cellular hypersensitization to noradrenaline caused by pertussis-toxin treatment. Biochemical Journal, 1996, 314, 761-768.	3.7	12
354	Agonist-Mediated Tyrosine Phosphorylation of Isoforms of the Shc Adapter Protein by the Î³ Opioid Receptor. Cellular Signalling, 1997, 9, 423-429.	3.6	12
355	Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening. Expert Opinion on Drug Discovery, 2010, 5, 461-474.	5.0	12
356	Binding to GDP-agarose identifies a novel 60kDa substrate for the insulin receptor tyrosyl kinase in mouse NIH-3T3 cells expressing high concentrations of the human insulin receptor. Biochemical and Biophysical Research Communications, 1989, 158, 743-748.	2.1	11
357	Guanine nucleotide binding proteins in neuroblastoma Å— glioma hybrid, NG108-15, cells. regulation of expression and function. International Journal of Biochemistry & Cell Biology, 1990, 22, 701-707.	0.5	11
358	Overexpression of Gs1± in NG108-15, neuroblastoma X glioma cells: effects on receptor regulation of the stimulatory adenylyl cyclase cascade. FEBS Letters, 1996, 397, 325-330.	2.8	11
359	Quantitative analysis of a cysteine351glycine mutation in the G protein Gi1±: effect on Î±2A-adrenoceptor-Gi1± fusion protein activation. FEBS Letters, 1998, 428, 17-22.	2.8	11
360	Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84. ACS Pharmacology and Translational Science, 2021, 4, 1598-1613.	4.9	11

#	ARTICLE	IF	CITATIONS
361	Opioid Regulation of Mu Receptor Internalisation: Relevance to the Development of Tolerance and Dependence. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 616-626.	1.4	11
362	Foetal calf serum enhances cholera toxin-catalysed ADP-ribosylation of the pertussis toxin-sensitive guanine nucleotide binding protein, Gi2, in rat glioma C6BU1 cells. <i>Cellular Signalling</i> , 1989, 1, 65-74.	3.6	10
363	Prostanoid-mediated downregulation of Gs in NG108 $\hat{\epsilon}$ 15 cells. <i>Biochemical Society Transactions</i> , 1991, 19, 81S-81S.	3.4	10
364	Guanine nucleotide regulatory protein alterations in young Milan hypertensive strain rats. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1994, 1225, 149-157.	3.8	10
365	Use of [³ H]Triphenylmethylphosphonium Cation for Estimating Membrane Potential in Neuroblastoma Cells. <i>Journal of Neurochemistry</i> , 1984, 43, 1515-1521.	3.9	9
366	Is Promiscuity of G Protein Interaction an Issue in the Classification of Receptors?. <i>Annals of the New York Academy of Sciences</i> , 1997, 812, 126-132.	3.8	9
367	Visualization of distinct patterns of subcellular redistribution of the thyrotropin-releasing hormone receptor-1 and Gq $\hat{\pm}$ /G11 $\hat{\pm}$ induced by agonist stimulation. <i>Biochemical Journal</i> , 1999, 340, 529.	3.7	9
368	Oligomeric structure of the $\hat{\pm}$ 1b-adrenoceptor: Comparisons with rhodopsin. <i>Vision Research</i> , 2006, 46, 4434-4441.	1.4	9
369	Functional interactions between the $\hat{\pm}$ 1b-adrenoceptor and G $\hat{\pm}$ 11 are compromised by de-palmitoylation of the G protein but not of the receptor. <i>Cellular Signalling</i> , 2006, 18, 1244-1251.	3.6	9
370	Role of metabotropic glutamate receptors in CNS disorders. , 2010, , 321-379.		9
371	Novel mutation in the AVPR2 gene in a Danish male with nephrogenic diabetes insipidus caused by ER retention and subsequent lysosomal degradation of the mutant receptor. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 158-163.	2.9	9
372	Distinct Agonist Regulation of Muscarinic Acetylcholine M2-M3 Heteromers and Their Corresponding Homomers. <i>Journal of Biological Chemistry</i> , 2015, 290, 14785-14796.	3.4	9
373	Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling. <i>ACS Pharmacology and Translational Science</i> , 2018, 1, 119-133.	4.9	9
374	Biochemical estimation of membrane potential in neuroblastoma cells. <i>Biochemical Society Transactions</i> , 1981, 9, 414-415.	3.4	8
375	Apparent down-regulation of muscarinic acetylcholine receptors of neuroblastoma cells by pilocarpine is due to occluded agonist. <i>European Journal of Pharmacology</i> , 1983, 91, 223-228.	3.5	8
376	Multiple heterotrimeric guanine nucleotide binding proteins: roles in the determination of cellular signalling specificity. <i>Biochemical Society Transactions</i> , 1992, 20, 135-140.	3.4	8
377	Reciprocal mutations of highly conserved residues in transmembrane helices 2 and 7 of the $\hat{\pm}$ 2A-adrenoceptor restore agonist activation of G11 $\hat{\pm}$. <i>Cellular Signalling</i> , 2002, 14, 139-144.	3.6	8
378	Engineering a V2 Vasopressin Receptor Agonist- and Regulator of G-Protein-Signaling-Sensitive G Protein. <i>Analytical Biochemistry</i> , 2002, 300, 212-220.	2.4	8

#	ARTICLE	IF	CITATIONS
379	Selectivity in the oligomerisation of G protein-coupled receptors. <i>Seminars in Cell and Developmental Biology</i> , 2004, 15, 263-268.	5.0	8
380	Structure-Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3577-3595.	6.4	8
381	Chemogenetic Approaches to Explore the Functions of Free Fatty Acid Receptor 2. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 191-202.	8.7	8
382	G Protein-Coupled Receptor GPR35 Suppresses Lipid Accumulation in Hepatocytes. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1835-1848.	4.9	8
383	Muscarinic Acetylcholine Receptors in Neuroblastoma Cells: Lack of Effect of Veratrum Alkaloids on Receptor Number. <i>Journal of Neurochemistry</i> , 1984, 43, 33-41.	3.9	7
384	Concurrent specific immunological detection of both primate and rodent forms of the guanine nucleotide binding protein G11 \pm following their coexpression. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1994, 1222, 369-374.	4.1	7
385	Chapter 16 Activation, cellular redistribution and enhanced degradation of the G proteins Gq α and G11 by endogenously expressed and transfected phospholipase C-coupled muscarinic m1 acetylcholine receptors. <i>Progress in Brain Research</i> , 1996, 109, 181-187.	1.4	7
386	Constitutive Activity of GPR40/FFA1. <i>Methods in Enzymology</i> , 2010, 484, 569-590.	1.0	7
387	The Role of miRNA in Stem Cell Pluripotency and Commitment to the Vascular Endothelial Lineage. <i>Microcirculation</i> , 2012, 19, 196-207.	1.8	7
388	The effect of sodium channel activators on muscarinic receptors of neuroblastoma cells. <i>FEBS Letters</i> , 1982, 148, 39-43.	2.8	6
389	Increased concentrations of proteins Gi1 and Gi2 in adipocytes from aged rats alter the sensitivity of adenylyl cyclase to inhibitory and stimulatory agonists. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 239-244.	3.4	6
390	The Use of Receptor G-Protein Fusion Proteins for the Study of Ligand Activity. <i>Receptors and Channels</i> , 2002, 8, 309-317.	1.1	6
391	Chapter 10 Hetero-Oligomerization of Chemokine Receptors. <i>Methods in Enzymology</i> , 2009, 461, 207-225.	1.0	6
392	<i>Erythro</i> -9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. <i>Biochemical Journal</i> , 2010, 432, 575-599.	3.7	6
393	Approaches to Characterize and Quantify Oligomerization of GPCRs. <i>Methods in Molecular Biology</i> , 2015, 1335, 95-105.	0.9	6
394	The Use of Biochemical Methods for Estimating Membrane Potential. <i>Progress in Brain Research</i> , 1982, 55, 321-329.	1.4	5
395	Reduction in accumulation of [3H]triphenylmethylphosphonium cation in neuroblastoma cells caused by optical probes of membrane potential. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1983, 762, 585-592.	4.1	5
396	Effects of prolonged treatment of adipocytes with PGE1, N6-phenylisopropyl adenosine and nicotinic acid on G-proteins and antilipolytic sensitivity. <i>Biochemical Society Transactions</i> , 1991, 19, 212S-212S.	3.4	5

#	ARTICLE	IF	CITATIONS
397	Endocrine disorders associated with mutations in guanine nucleotide binding proteins. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1996, 10, 177-187.	1.0	5
398	Chapter 24. Oligomerisation of G protein-coupled receptors. <i>Annual Reports in Medicinal Chemistry</i> , 2000, 35, 271-279.	0.9	5
399	Kinetic analysis of the internalization and recycling of [3H]TRH and C-terminal truncations of the long isoform of the rat thyrotropin-releasing hormone receptor-1. <i>Biochemical Journal</i> , 2000, 346, 711.	3.7	5
400	Regulation of the avidity of ternary complexes containing the human 5-HT1A receptor by mutation of a receptor contact site on the interacting G protein $\beta\gamma$ subunit. <i>British Journal of Pharmacology</i> , 2002, 137, 345-352.	5.4	5
401	Allosteric modulation and constitutive activity of fusion proteins between the adenosine A1 receptor and different 351Cys-mutated Gi $\beta\gamma$ -subunits. <i>European Journal of Pharmacology</i> , 2004, 499, 91-98.	3.5	5
402	Capillary Electrophoresis Assay for G Protein-Coupled Receptor-Mediated GTPase Activity. <i>Analytical Chemistry</i> , 2007, 79, 1158-1163.	6.5	5
403	An arginine residue is the site of receptor-stimulated, cholera toxin-catalysed ADP-ribosylation of pertussis toxin-sensitive G-proteins. <i>Cellular Signalling</i> , 1993, 5, 485-493.	3.6	4
404	Cyclic AMP differentially regulates the expression of the $\beta\gamma$ -subunits of Gs, Gq and G11 G-proteins and their mRNA levels in rat C6 glioma cells. <i>Biochemical Society Transactions</i> , 1995, 23, 10S-10S.	3.4	4
405	Palmitoylation negative mutants of murine G11 $\beta\gamma$ have decreased ability to interact with the plasma membrane when expressed in COS-1 cells. <i>Biochemical Society Transactions</i> , 1995, 23, 9S-9S.	3.4	4
406	Regulation of cellular Gs $\beta\gamma$ levels and basal adenylyl cyclase activity by expression of the β 2-adrenoceptor in neuroblastoma cell lines. <i>Molecular and Cellular Biochemistry</i> , 1995, 149-150, 213-216.	3.1	4
407	Isolation and characterization of a novel human RGS mutant displaying gain-of-function activity. <i>Cellular Signalling</i> , 2008, 20, 323-336.	3.6	4
408	The First 50 Years of Molecular Pharmacology. <i>Molecular Pharmacology</i> , 2015, 88, 139-140.	2.3	4
409	M3 muscarinic acetylcholine receptor facilitates the endocytosis of mu opioid receptor mediated by morphine independently of the formation of heteromeric complexes. <i>Cellular Signalling</i> , 2017, 35, 208-222.	3.6	4
410	The M ₁ muscarinic receptor is present in situ as a ligand-regulated mixture of monomers and oligomeric complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	4
411	G-proteins and second messengers in mitogenesis. <i>Progress in Growth Factor Research</i> , 1989, 1, 161-177.	1.6	3
412	Characterization of heterotrimeric G-proteins in adult <i>Acanthocheilonema viteae</i> . <i>Biochemical Journal</i> , 1996, 320, 459-466.	3.7	3
413	Adenylyl cyclase isoform-specific signaling of GPCRs. , 0, , 189-216.		3
414	Fatty airways: a source of good and bad fats?. <i>European Respiratory Journal</i> , 2019, 54, 1902060.	6.7	3

#	ARTICLE	IF	CITATIONS
415	Down-regulation of the $\hat{I}\pm$ -subunits of Gi subtypes by prolonged incubation of adipocytes with N6-phenylisopropyl adenosine. <i>Biochemical Society Transactions</i> , 1990, 18, 487-487.	3.4	2
416	Phosphorylation of Gi in intact cells. <i>Trends in Biochemical Sciences</i> , 1990, 15, 13.	7.5	2
417	Identification and Analysis of Function of Heterotrimeric Guanine Nucleotide-Binding Proteins Expressed in Neural Tissue. , 1992, , 1-56.		2
418	Activation of the gonadotropin releasing hormone receptor of $\hat{I}\pm$ T3 cells results in downregulation of the $\hat{I}\pm$ subunits of both Gq/G11. <i>Biochemical Society Transactions</i> , 1993, 21, 498S-498S.	3.4	2
419	Receptor availability defines the extent of agonist-mediated G-protein down-regulation in neuroblastoma \hat{A} — glioma hybrid cells transfected to express the \hat{I}^2 -adrenoceptor. <i>FEBS Letters</i> , 1994, 355, 166-170.	2.8	2
420	Agonist-Mediated Turnover of G-Protein $\hat{I}\pm$ -Subunit Palmitoyl Groups: Role in Membrane Insertion. , 1998, 88, 241-248.		2
421	G protein-coupled receptors: oligomerisation and association with accessory proteins. <i>Seminars in Cell and Developmental Biology</i> , 2004, 15, 261.	5.0	2
422	Time-resolved FRET approaches to study GPCR complexes. , 0, , 67-89.		2
423	The Use of Spatial Intensity Distribution Analysis to Examine G Protein-Coupled Receptor Oligomerization. , 2017, , 15-38.		2
424	Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2. <i>ChemMedChem</i> , 2021, 16, 3326-3341.	3.2	2
425	Defining the Functional Equivalence of Wild-Type and Chemically Engineered G Protein-Coupled Receptors. <i>NeuroMethods</i> , 2015, , 1-28.	0.3	2
426	Free fatty acid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	2
427	The use of receptor G-protein fusion proteins for the study of ligand activity. <i>Receptors and Channels</i> , 2002, 8, 309-17.	1.1	2
428	The use of lipophilic anions to facilitate uptake of triphenylmethylphosphonium cation in membrane-potential studies in neuroblastoma cells. <i>Biochemical Society Transactions</i> , 1982, 10, 375-376.	3.4	1
429	Expression of G-protein \hat{I}^2 -subunit in lean and obese Zucker rats and streptozotocin-induced diabetic and normal rats. <i>Biochemical Society Transactions</i> , 1989, 17, 667-668.	3.4	1
430	Identification and analysis of two distinct isoforms of the guanine nucleotide-binding protein G0 in NG108-15 cells. <i>Biochemical Society Transactions</i> , 1990, 18, 396-399.	3.4	1
431	Agonist activation of transfected human M1 muscarinic acetylcholine receptor in Chinese hamster ovary cells results in concurrent downregulation of Gq $\hat{I}\pm$ and G11 $\hat{I}\pm$. <i>Biochemical Society Transactions</i> , 1993, 21, 497S-497S.	3.4	1
432	Stimulation of p70S6 kinase phosphorylation by the A2A adenosine receptor in primary human endothelial cells and in CHO cells heterologously expressing the receptor. <i>Drug Development Research</i> , 1998, 45, 140-150.	2.9	1

#	ARTICLE	IF	CITATIONS
433	Novel approaches to enhance the detection of receptor constitutive activity and inverse agonists. International Congress Series, 2003, 1249, 15-25.	0.2	1
434	Identification and Quantitation of G-Protein $\hat{\pm}$ -Subunits. , 2004, 259, 207-224.		1
435	The quaternary structure of G protein-coupled receptors. FEBS Journal, 2005, 272, 2913-2913.	4.7	1
436	Functional Complementation and the Analysis of GPCR Dimerization. Contemporary Clinical Neuroscience, 2005, , 267-285.	0.3	1
437	17-P003 Discovery of small molecules to control human embryonic stem cell fate. Mechanisms of Development, 2009, 126, S271-S272.	1.7	1
438	GPCR-G protein fusions: Use in functional dimerization analysis. , 2010, , 53-66.		1
439	Novel Assay Technologies for the Discovery of G Protein-Coupled Receptor Drugs. Neuromethods, 2011, , 231-253.	0.3	1
440	THE USE OF SPECIFIC ANTISERA TO STUDY THE DEVELOPMENTAL REGULATION OF GUANINE NUCLEOTIDE BINDING PROTEINS. , 1987, , 415-418.		1
441	U937 cell differentiation: G protein alterations and interaction with the chemotactic peptide receptor. Biochemical Society Transactions, 1991, 19, 98S-98S.	3.4	0
442	Signal transduction in Rat-1 fibroblasts expressing high levels of the $\hat{\pm}2$ -C10 adrenergic receptor. Biochemical Society Transactions, 1991, 19, 102S-102S.	3.4	0
443	38 Alterations in the levels and function of guanine nucleotide regulatory proteins in Milan hypertensive rats. Journal of Hypertension, 1993, 11, S412.	0.5	0
444	High level expression of mammalian G protein $\hat{\pm}$ subunit Gq subtypes in Escherichia coli. Biochemical Society Transactions, 1995, 23, 12S-12S.	3.4	0
445	Interaction of the $\hat{\pm}2$ -adrenoceptor with epitope-tagged Gs $\hat{\pm}$ in NG108-15 cells. Biochemical Society Transactions, 1995, 23, 7S-7S.	3.4	0
446	Agonist regulation of high affinity [3H] forskolin binding as a measure of Gs $\hat{\pm}$ - adenylyl cyclase interactions. Biochemical Society Transactions, 1995, 23, 8S-8S.	3.4	0
447	Signalling characteristics of thyrotropin releasing hormone (TRH) receptor isoforms. Biochemical Society Transactions, 1995, 23, 11S-11S.	3.4	0
448	Go1 $\hat{\pm}$ palmitoylation: Its contribution to $\hat{\pm}2$ C10 adrenoceptor - Go1 $\hat{\pm}$ coupling. Biochemical Society Transactions, 1995, 23, 406S-406S.	3.4	0
449	Internalisation of Wild type and Mutant $\hat{\pm}1B$ -Adrenergic Receptors. Biochemical Society Transactions, 1999, 27, A114-A114.	3.4	0
450	Diversity in the signaling and regulation of G protein-coupled receptors. Biochemical Society Transactions, 1999, 27, A24-A24.	3.4	0

#	ARTICLE	IF	CITATIONS
451	Receptor-GFP Fusion Proteins; A study of Drug Effects on Receptor Internalisation, Trafficking and Expression. Biochemical Society Transactions, 1999, 27, A114-A114.	3.4	0
452	G protein activation and effector regulation by the human 5-HT1A receptor and the β subunit of Gi1 fusion proteins. Biochemical Society Transactions, 1999, 27, A114-A114.	3.4	0
453	Cell Cycle Regulation in Rat 1 Fibroblasts Expressing a Murine Delta Opioid Gi Linked Receptor. Biochemical Society Transactions, 1999, 27, A114-A114.	3.4	0
454	Construction and Analysis of β 2A-Adrenoceptor Gi/Go β -Subunit Fusion Proteins. Biochemical Society Transactions, 1999, 27, A115-A115.	3.4	0
455	Characterisation of Three Subtypes of Rat Thyrotropin Releasing Hormone Receptor. Biochemical Society Transactions, 1999, 27, A115-A115.	3.4	0
456	Activation and Desensitisation of the Thyrotropin-Releasing Hormone Receptor Visualised by Monitoring Cellular Redistribution of a β 2-arrestin-1-Green Fluorescent Protein Fusion Protein. Biochemical Society Transactions, 1999, 27, A118-A118.	3.4	0
457	Analysis of Protein Palmitoylation. , 2002, , 633-640.		0
458	Monitoring Receptor Dimerisation. Medicinal Chemistry Research, 2004, 13, 18-24.	2.4	0
459	Functional studies of isolated GPCR-G protein complexes in the membrane bilayer of lipoprotein particles. , 0, , 32-52.		0
460	Signaling of dopamine receptor homo- and heterooligomers. , 0, , 90-110.		0
461	Functional consequences of chemokine receptor dimerization. , 0, , 111-124.		0
462	Kinetics of GPCR, G protein, and effector activation. , 0, , 145-158.		0
463	G protein-independent and β 2 arrestin-dependent GPCR signaling. , 0, , 217-230.		0
464	Assays to read GPCR modulation and signaling. , 0, , 231-246.		0
465	7TM receptor functional selectivity. , 0, , 270-286.		0
466	Using Receptor-G-Protein Chimeras to Screen for Drugs. , 2003, , 619-621.		0
467	Polymorphisms in murine histamine receptor H1 leading to differential cell surface expression influence autoimmune disease progression. FASEB Journal, 2008, 22, 667.2.	0.5	0
468	Expression of Two Isoforms of the Guanine Nucleotide Binding Protein,Go, IN NG108â€™15 Neuroglioma Cells. , 1991, , 221-235.		0

#	ARTICLE	IF	CITATIONS
469	The Use of Stably Transfected Cell Lines in the Analysis of Functional Interactions between $G\alpha_{i1}$ & $G\alpha_{i2}$ and the β_2 Adrenoceptor. , 1995, , 99-113.		0
470	Identification of stable opioid receptor Go-protein complexes using GTP-binding protein selective antisera. , 1995, , 87-98.		0
471	Regulation of cellular $G\alpha$ levels and basal adenylyl cyclase activity by expression of the β_2 -adrenoceptor in neuroblastoma cell lines. , 1995, , 213-216.		0
472	Mechanism of Gonadotrophin Releasing Hormone Receptor Mediated Regulation of G-Proteins in Clonal Pituitary Gonadotrophs. , 1996, , 193-201.		0